Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

DF Stojdl, B Lichty, S Knowles, R Marius, H Atkins… - Nature medicine, 2000 - nature.com
Interferons are circulating factors that bind to cell surface receptors, activating a signaling
cascade, ultimately leading to both an antiviral response and an induction of growth inhibitory …

[HTML][HTML] VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

…, S Knowles, R Marius, J Reynard, L Poliquin, H Atkins… - Cancer cell, 2003 - cell.com
Ideally, an oncolytic virus will replicate preferentially in malignant cells, have the ability to
treat disseminated metastases, and ultimately be cleared by the patient. Here we present …

Quadrature-free implementation of discontinuous Galerkin method for hyperbolic equations

HL Atkins, CW Shu - AIAA journal, 1998 - arc.aiaa.org
A discontinuous Galerkin formulation that avoids the use of discrete quadrature formulas is
described and applied to linear and nonlinear test problems in one and two space …

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

HL Atkins, M Bowman, D Allan, G Anstee, DL Arnold… - The Lancet, 2016 - thelancet.com
Background Strong immunosuppression, including chemotherapy and immune-depleting
antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been …

[HTML][HTML] Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

…, M Daneshmand, K Speth, D Kirn, JA McCart, H Atkins… - Molecular Therapy, 2007 - cell.com
Oncolytic viruses (OVs) are selected or designed to eliminate malignancies by direct infection
and lysis of cancer cells. In contrast to this concept of direct tumor lysis by viral infection, …

Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis

PA Muraro, M Pasquini, HL Atkins, JD Bowen… - JAMA …, 2017 - jamanetwork.com
Importance Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in
aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies. …

[HTML][HTML] Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR

…, T Ishii, M Dubé, BC Vanderhyden, HL Atkins… - Journal of Biological …, 1999 - ASBMB
The interferon-inducible, double-stranded RNA-dependent protein kinase PKR has been
implicated in anti-viral, anti-tumor, and apoptotic responses. Others have attempted to examine …

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

MS Freedman, A Bar-Or, HL Atkins… - Multiple Sclerosis …, 2010 - journals.sagepub.com
Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms
of repair to the damaged central nervous system. Cell-based therapies may provide a new …

Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions

JT Chen, DL Collins, HL Atkins… - Annals of …, 2008 - Wiley Online Library
Objective To assess demyelination and remyelination in vivo in acute gadolinium (Gd)‐enhancing
lesions of multiple sclerosis (MS). Methods We measured significant changes in …

[HTML][HTML] Targeting tumor vasculature with an oncolytic virus

…, MM Stanford, BD Lichty, A Fenster, D Kirn, H Atkins… - Molecular Therapy, 2011 - cell.com
Oncolytic viruses (OVs) have been engineered or selected for cancer cell-specific infection
however, we have found that following intravenous administration of vesicular stomatitis virus …